Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma

Punke, Alexandra P.; Waddell, J. Aubrey; Solimando, Dominic A.

doi:10.1310/hpj5201-27

Cited by 7 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MM, solitary plasmacytoma of bone and extra-medullary plasmacytoma are the three chief clinical entities of plasma cell myeloma/plasmacytoma. [ 7 ] Calvarium, mandible, pelvic girdle, sternum, clavicle and proximal sections of the humerus and femur are all common sites for myeloma infiltrates. It is common in patients older than 50 years of age, with a peak incidence rate of 60–70 years.…”

Section: Discussionmentioning

confidence: 99%

“…Hence, based on immunological profile, the presence of M band on serum electrophoresis, bone marrow biopsy and imaging findings of extensive bone lesions, the diagnosis of MM was made. After referral to Medical Oncology, the patient was advised for chemotherapeutic lenalidomide, bortezomib and dexamethasone regimen[ 7 ] cycle that was repeated every 21 days, without any side effects. At one year follow up, resolution of ‘punched out lesions’ can be observed on plain radiographs i.e.…”

Section: Ase R Eportmentioning

confidence: 99%

See 1 more Smart Citation

Oral Manifestations of Malignant Immunoglobinopathy Hidden in Plain Sight - A Rare Case Report

Sharma

Singh

Hirani

et al. 2023

Annals of Maxillofacial Surgery

View full text Add to dashboard Cite

Rationale Radiolucent lesions over the angle–body region of the mandible are frequently difficult to diagnose but crucial to provide patient-centred care. Patient Concerns An elderly female presented with a painless slow-growing swelling over her left lower face for one year, radiographically appearing as a well-defined unilocular radiolucency over the left body of the mandible. Diagnosis Aspiration was negative, and biopsy was inconclusive. Further imaging, bone marrow biopsy, immune profile and serum electrophoresis confirmed the diagnosis of multiple myeloma. Treatment She was referred to Medical Oncology for chemotherapy of lenalidomide, bortezomib and dexamethasone regimen cycle that was repeated every 21 days. Outcomes There was no increase in swelling, and radiographically ‘punched-out’ lesions were reduced significantly. Take- Away Lessons Maxillofacial clinicians should be attentive to the oral manifestations of underlying disease, have a high index of suspicion and start the treatment promptly to increase chances of a favourable outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Ase R Eportmentioning

confidence: 99%

Oral Manifestations of Malignant Immunoglobinopathy Hidden in Plain Sight - A Rare Case Report

Sharma

Singh

Hirani

et al. 2023

Annals of Maxillofacial Surgery

View full text Add to dashboard Cite

show abstract

“…RVd is likely to induce emesis in some patients (<30%); therefore, antiemetic prophylaxis can be given on bortezomib treatment days, as needed. 56 Optimal use of granulocyte colony-stimulating factor prophylaxis in this population is dynamic, and it may be considered for neutropenia management. Antiviral prophylaxis is considered mandatory against varicella zoster, while antibacterial prophylaxis is recommended for some patients based on their individual risk factors.…”

Section: Rvd: Adverse Events and Managementmentioning

confidence: 99%

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson,

Durie,

Rosiñol

et al. 2023

haematol

View full text Add to dashboard Cite

To improve patient outcomes in the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient prognosis becomes worse after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet against both doublets and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of NDMM therapy, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM.

show abstract

“…FISH study on BM showed 8.5% with 13q14.3 deletion and no abnormality on chromosome 11; normal karyotype. Ibrutinib was discontinued and the patient was started on palliative radiation to the spine followed by RVD regimen 13 (Lenalidomide [Revlimid ® ] 25 mg orally day 1‐14; Bortezomib [Velcade ® 1.3 mg/m 2 subcutaneously on days 1,4,8,11; and Dexamethasone 40 mg orally on days 1,8,15). Treatment was repeated every 28 days.…”

Section: Case Presentationmentioning

confidence: 99%

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy

Al‐Katib

Gaith

Sano

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma

Cited by 7 publications

References 16 publications

Oral Manifestations of Malignant Immunoglobinopathy Hidden in Plain Sight - A Rare Case Report

Oral Manifestations of Malignant Immunoglobinopathy Hidden in Plain Sight - A Rare Case Report

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy

Contact Info

Product

Resources

About